RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

6 3 月, 2026

One Min Read

10 Views

原文: https://finance.yahoo.com/news/rbc-capital-lowers-price-target-152046349.html

Last Update: 6 3 月, 2026

Written By

Other Articles

Previous

H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating

Next

Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating

Related Posts

Powerball jackpot soars to $1.3 billion. Here’s what the winner will take home after taxes.

1 Min Read

What is force-placed car insurance, and when do lenders require it?

1 Min Read

Do you need collateral for a personal loan? See when it might help.

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept